25iP-NBOMe

Leave a Comment / NBxx / By

Summary

25iP-NBOMe (2C-iP-NBOMe, NBOMe-2C-iP) is a compound derived from the phenethylamine hallucinogen 2C-iP, renowned for its exceptional potency as an agonist for the human 5-HT2A receptor.

Identifiers
IUPAC name
CAS Number1391487-83-4 
PubChem CID118796426
ChemSpider52085379 
UNII575702U55U
Chemical and physical data
FormulaC21H29NO3
Molar mass343.467 g·mol−1

Toxicity and harm potential

NBOMe compounds are frequently linked to severe toxicity and fatalities, often exhibiting neurotoxic and cardiotoxic properties. Autonomic dysfunction, including sympathomimetic toxicity such as vasoconstriction, hypertension, and tachycardia, is commonly observed with NBOMe use, accompanied by hallucinations and a range of severe symptoms including agitation, seizure, hyperthermia, hypertonia, and rhabdomyolysis. Notably, NBOMe intoxication often presents signs of serotonin syndrome and a heightened risk of seizures compared to other psychedelics.
These compounds are often sold as LSD, creating a dangerous misconception as their safety profiles significantly differ. Incidents involving NBOMe ingestion mistaken for LSD have resulted in fatalities and are additionally associated with self-harm and suicide under the drug’s influence. However, due to limited documentation, the long-term effects of NBOMe use remain unknown.
NBOMe compounds are administered sublingually, inducing a distinct metallic taste and numbness in the mouth. This effect is considered one of the primary discriminants between NBOMe and LSD consumption. Additionally, their high potency at 5-HT receptors, particularly 5-HT2B, has been implicated in cardiac valvulopathy and stimulant-type cardiovascular effects.
In vitro studies have highlighted the neurotoxicity of 25C-NBOMe, demonstrating its cytotoxic effects on neuronal and cardiomyocyte cell lines. While the toxicity of these compounds has been observed in various animal models, further research is needed to understand its full impact, especially on pregnant women and their fetuses.
Currently, there is no specific antidote for NBOMe intoxication, and treatments primarily focus on managing acute symptoms, including the administration of benzodiazepines, antipsychotic drugs, and beta-blockers. Specific interventions address complications such as rhabdomyolysis, metabolic acidosis, and acute kidney injury, which may arise from NBOMe use.

Legality

In the United Kingdom, this compound falls under the category of Class A drugs, according to the N-benzylphenethylamine catch-all clause stipulated in the Misuse of Drugs Act 1971.

FAQ

  • What is 25iP-NBOMe?
  • 25iP-NBOMe is a derivative of the phenethylamine hallucinogen 2C-iP, known for its potent agonist activity on the human 5-HT2A receptor.
  • How does 25iP-NBOMe compare to 2C-iP?
  • 25iP-NBOMe is a modified version of 2C-iP, exhibiting enhanced potency and binding affinity for the 5-HT2A receptor compared to its precursor.
  • What are the critical effects of 25iP-NBOMe?
  • Users typically experience psychedelic effects such as altered perception, hallucinations, and sensory distortions, often accompanied by changes in mood and cognition.
  • Is 25iP-NBOMe known for any particular risks or dangers?
  • Like other compounds in the NBOMe family, 25iP-NBOMe is associated with potential risks of severe toxicity and adverse reactions, which could lead to life-threatening consequences.
  • How is 25iP-NBOMe administered?
  • Typically, 25iP-NBOMe is taken sublingually or through other oral mucosal routes. Users should be cautious about the accurate dosage to avoid accidental overdose.
  • What precautions should be taken while using 25iP-NBOMe?
  • Awareness of the substance’s potent nature and potential risks is imperative. Accurate dosing, proper identification, and harm reduction practices are essential when handling 25iP-NBOMe.
  • What are the legal implications of 25iP-NBOMe?
  • The legal status of 25iP-NBOMe varies across different jurisdictions. It is advisable to be informed about the regulatory measures in your specific region to avoid any legal complications.
  • Are there any known long-term effects of 25iP-NBOMe use?
  • Due to limited research and documentation, the long-term effects of 25iP-NBOMe still need to be discovered. Users are cautioned to be mindful of potential risks and conduct responsible usage.
  • What should be done in an emergency or adverse reaction to 25iP-NBOMe?
  • In the event of any adverse effects or emergencies related to 25iP-NBOMe consumption, seeking immediate medical assistance is crucial. Inform the medical professionals about the specific substance ingested for appropriate treatment.
  • How can the risks associated with 25iP-NBOMe use be minimized?
  • Risk reduction practices include accurate dosing, ensuring product purity, testing substances for authenticity, and being informed about the potential dangers and proper handling of 25iP-NBOMe.

References

  1. David W, Roumen S, Andrew C, Paul D (6 February 2015). “Prevalence of use and acute toxicity associated with the use of NBOMe drugs”. Clinical Toxicology. 53 (2): 85–92. doi:10.3109/15563650.2015.1004179. PMID 25658166.
  2. Sean I, Joe R, Jennifer S, and Shaun G (28 March 2022). “A cluster of 25B-NBOH poisonings following exposure to powder sold as lysergic acid diethylamide (LSD)”. Clinical Toxicology. 60 (8): 966–969. doi:10.1080/15563650.2022.2053150. PMID 35343858. S2CID 247764056.
  3. Amy E, Katherine W, John R, Sonyoung K, Robert J, Aaron J (December 2018). “Neurochemical pharmacology of psychoactive substituted N-benzylphenethylamines: High potency agonists at 5-HT2A receptors”. Biochemical Pharmacology. 158: 27–34. doi:10.1016/j.bcp.2018.09.024. PMC 6298744. PMID 30261175.
  4. Jolanta Z, Monika K, and Piotr A (26 February 2020). “NBOMes–Highly Potent and Toxic Alternatives of LSD”. Frontiers in Neuroscience. 14: 78. doi:10.3389/fnins.2020.00078. PMC 7054380. PMID 32174803.
  5. Lipow M, Kaleem SZ, Espiridion E (30 March 2022). “NBOMe Toxicity and Fatalities: A Review of the Literature”. Transformative Medicine. 1 (1): 12–18. doi:10.54299/tmed/msot8578. ISSN 2831-8978. S2CID 247888583.
  6. Micaela T, Sabrine B, Raffaella A, Giorgia C, Beatrice M, Tatiana B, Federica B, Giovanni S, Francesco B, Fabio G, Krystyna G, Matteo M (21 April 2022). “Effect of -NBOMe Compounds on Sensorimotor, Motor, and Prepulse Inhibition Responses in Mice in Comparison With the 2C Analogs and Lysergic Acid Diethylamide: From Preclinical Evidence to Forensic Implication in Driving Under the Influence of Drugs”. Front Psychiatry. 13: 875722. doi:10.3389/fpsyt.2022.875722. PMC 9069068. PMID 35530025.
  7. Cristina M, Matteo M, Nicholas P, Maria C, Micaela T, Raffaella A, Maria L (12 December 2019). “Neurochemical and Behavioral Profiling in Male and Female Rats of the Psychedelic Agent 25I-NBOMe”. Frontiers in Pharmacology. 10: 1406. doi:10.3389/fphar.2019.01406. PMC 6921684. PMID 31915427.
  8. Anna R, Dino L, Julia R, Daniele B, Marius H, Matthias L (December 2015). “Receptor interaction profiles of novel N-2-methoxybenzyl (NBOMe) derivatives of 2,5-dimethoxy-substituted phenethylamines (2C drugs)”. Neuropharmacology. 99: 546–553. doi:10.1016/j.neuropharm.2015.08.034. ISSN 1873-7064. PMID 26318099. S2CID 10382311.
  9. David W, Roumen S, Andrew C, Paul D (6 February 2015). “Prevalence of use and acute toxicity associated with the use of NBOMe drugs”. Clinical Toxicology. 53 (2): 85–92. doi:10.3109/15563650.2015.1004179. PMID 25658166. S2CID 25752763.
  10. Humston C, Miketic R, Moon K, Ma P, Tobias J (2017-06-05). “Toxic Leukoencephalopathy in a Teenager Caused by the Recreational Ingestion of 25I-NBOMe: A Case Report and Review of Literature”. Journal of Medical Cases. 8 (6): 174–179. doi:10.14740/jmc2811w. ISSN 1923-4163.
  11. Justin P, Stephen R, Kylin A, Alphonse P, Michelle P (2015). “Analysis of 25I-NBOMe, 25B-NBOMe, 25C-NBOMe and Other Dimethoxyphenyl-N-[(2-Methoxyphenyl) Methyl]Ethanamine Derivatives on Blotter Paper”. Journal of Analytical Toxicology. 39 (8): 617–623. doi:10.1093/jat/bkv073. PMC 4570937. PMID 26378135.
  12. Morini L, Bernini M, Vezzoli S, Restori M, Moretti M, Crenna S, et al. (October 2017). “Death after 25C-NBOMe and 25H-NBOMe consumption”. Forensic Science International. 279: e1–e6. doi:10.1016/j.forsciint.2017.08.028. PMID 28893436.
  13. Byard RW, Cox M, Stockham P (November 2016). “Blunt Craniofacial Trauma as a Manifestation of Excited Delirium Caused by New Psychoactive Substances”. Journal of Forensic Sciences. 61 (6): 1546–1548. doi:10.1111/1556-4029.13212. PMID 27723094. S2CID 4734566.
  14. Sabastian LP, Christoffer B, Martin H, Martin AC, Jan K, Jesper LK (14 February 2014). “Correlating the Metabolic Stability of Psychedelic 5-HT2A Agonists with Anecdotal Reports of Human Oral Bioavailability”. Neurochemical Research. 39 (10): 2018–2023. doi:10.1007/s11064-014-1253-y. PMID 24519542. S2CID 254857910.
  15. Adam H (18 January 2017). “Pharmacology and Toxicology of N-Benzylphenethylamine (“NBOMe”) Hallucinogens”. Neuropharmacology of New Psychoactive Substances. Current Topics in Behavioral Neurosciences. Vol. 32. Springer. pp. 283–311. doi:10.1007/7854_2016_64. ISBN 978-3-319-52444-3. PMID 28097528.
  16. Boris D, Cristian C, Marcelo K, Edwar F, Bruce KC (August 2016). “Analysis of 25 C NBOMe in Seized Blotters by HPTLC and GC–MS”. Journal of Chromatographic Science. 54 (7): 1153–1158. doi:10.1093/chromsci/bmw095. PMC 4941995. PMID 27406128.
  17. Francesco SB, Ornella C, Gabriella A, Giuseppe V, Rita S, Flaminia BP, Eduardo C, Pierluigi S, Giovanni M, Guiseppe B, Fabrizio S (3 July 2014). “25C-NBOMe: preliminary data on pharmacology, psychoactive effects, and toxicity of a new potent and dangerous hallucinogenic drug”. BioMed Research International. 2014: 734749. doi:10.1155/2014/734749. PMC 4106087. PMID 25105138.
  18. Adam JP, Simon HT, Simon LH (September 2021). “Pharmacology and toxicology of N-Benzyl-phenylethylamines (25X-NBOMe) hallucinogens”. Novel Psychoactive Substances: Classification, Pharmacology and Toxicology (2 ed.). Academic Press. pp. 279–300. doi:10.1016/B978-0-12-818788-3.00008-5. ISBN 978-0-12-818788-3. S2CID 240583877.
  19. Rothman RB, Baumann MH, Savage JE, Rauser L, McBride A, Hufeisen SJ, Roth BL (Dec 2000). “Evidence for possible involvement of 5-HT(2B) receptors in the cardiac valvulopathy associated with fenfluramine and other serotonergic medications”. Circulation. 102 (23): 2836–41. doi:10.1161/01.CIR.102.23.2836. PMID 11104741.
  20. Fitzgerald LW, Burn TC, Brown BS, Patterson JP, Corjay MH, Valentine PA, Sun JH, Link JR, Abbaszade I, Hollis JM, Largent BL, Hartig PR, Hollis GF, Meunier PC, Robichaud AJ, Robertson DW (Jan 2000). “Possible role of valvular serotonin 5-HT(2B) receptors in the cardiopathy associated with fenfluramine”. Molecular Pharmacology. 57 (1): 75–81. PMID 10617681.
  21. Roth BL (Jan 2007). “Drugs and valvular heart disease”. The New England Journal of Medicine. 356 (1): 6–9. doi:10.1056/NEJMp068265. PMID 17202450.
  22. Xu P, Qiu Q, Li H, Yan S, Yang M, Naman CB, et al. (26 February 2019). “25C-NBOMe, a Novel Designer Psychedelic, Induces Neurotoxicity 50 Times More Potent Than Methamphetamine In Vitro”. Neurotoxicity Research. 35 (4): 993–998. doi:10.1007/s12640-019-0012-x. PMID 30806983. S2CID 255763701.
  23. Álvarez-Alarcón N, Osorio-Méndez JJ, Ayala-Fajardo A, Garzón-Méndez WF, Garavito-Aguilar ZV (2021). “Zebrafish and Artemia salina in vivo evaluation of the recreational 25C-NBOMe drug demonstrates its high toxicity”. Toxicology Reports. 8: 315–323. doi:10.1016/j.toxrep.2021.01.010. ISSN 2214-7500. PMC 7868744. PMID 33598409.
  24. “The Misuse of Drugs Act 1971 (Ketamine etc.) (Amendment) Order 2014”. www.legislation.gov.uk.

Leave a Comment

Your email address will not be published. Required fields are marked *